Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).

Affiliation auteurs!!!! Error affiliation !!!!
TitreFinal results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).
Type de publicationJournal Article
Year of Publication2019
AuteursBaciarello G, Delva R, Gravis G, Tazi Y, Theodore C, Gross-Goupil M, Bompas E, Joly F, Lharidon T, Hon TNguyen Tan, Barthelemy P, Culine S, Berdah JFrancois, Deblock M, Beuzeboc P, Flechon A, Cheneau C, Martineau G, Borget I, Fizazi K
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume37
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2019.37.15_suppl.5017